Latest Biotech Startup Funding Rounds
Financing for drug discovery, therapeutics and biological technologies, with the development context behind each round.
- Rounds
- 471 Jan 1 – Oct 24, 2026
- Disclosed funding
- $19.6B 400 disclosed amounts
- Median round
- $20M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| A AntheiaCompany profile Antheia manufactures pharmaceutical ingredients through biosynthesis, using controlled fermentation to supply drugmakers with key starting materials and active ingredients. Antheia manufactures pharmaceutical ingredients through biosynthesis, using controlled fermentation to supply drugmakers with key starting materials and active ingredients. | $9M | BioMaP project agreement expansionUndisclosed | Biotech | United States | Investors Undisclosed | |
| AG Alithea GenomicsCompany profile Alithea Genomics supplies RNA-sequencing preparation kits and services for laboratories running large gene-expression and drug-screening studies. Alithea Genomics supplies RNA-sequencing preparation kits and services for laboratories running large gene-expression and drug-screening studies. | CHF 3M | Seed | Biotech | Switzerland | Investors | |
| S ShellworksCompany profile Develops bio-based plastic alternative materials for packaging and consumer goods Develops bio-based plastic alternative materials for packaging and consumer goods | $15M | Series A | Biotech, Climate tech | United Kingdom | Investors | |
| M MycoverseCompany profile Developing fungal-based biological crop protection solutions using AI-driven discovery platform Developing fungal-based biological crop protection solutions using AI-driven discovery platform | €2.4M | Pre-SeedPre-seed | Biotech, Agritech | Denmark | Investors | |
| PT Poplar TherapeuticsCompany profile Developing a new class of anti-IgE therapy to treat food allergy and other atopic conditions Developing a new class of anti-IgE therapy to treat food allergy and other atopic conditions | $45M | Series A+Series A | Biotech | United States | Investors | |
| A ALORACompany profile Agricultural biotechnology company developing gene-edited crop traits to improve yield under heat and salinity stress. Agricultural biotechnology company developing gene-edited crop traits to improve yield under heat and salinity stress. | Undisclosed | Undisclosed | Biotech, Agritech | United Kingdom | Investors | |
| b Develops an AI-powered bioproduction platform for industrial ingredients | €7M | Seed | Biotech | France | Investors | |
| A AntiverseCompany profile Antiverse designs therapeutic antibodies for difficult drug targets using generative AI, engineered cell lines and in-house laboratory testing. Antiverse designs therapeutic antibodies for difficult drug targets using generative AI, engineered cell lines and in-house laboratory testing. | $9.3M | Series A | Biotech, Healthtech | United Kingdom | Investors | |
| B Develops AI platform for targeted crop protection solutions | $3.8M | Seed | Biotech, Agritech | United Kingdom | Investors | |
| OB Develops AI-driven models to decode human microbiology | $3.5M | Pre-SeedPre-seed | Biotech | United Kingdom | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · From Jan 1, 2026
- 1RA Capital Management
Estuary Biotherapeutics, Circle Pharma, Inc., Solstice Oncology
22rounds3led - 2Janus Henderson Investors
Star Therapeutics, OMass Therapeutics, Soufflé Therapeutics
15rounds1led - 3Eli Lilly and Company
BigHat Biosciences, Circle Pharma, Inc., Moonwalk Biosciences
15rounds0led - 4ARCH Venture Partners
Soufflé Therapeutics, Encoded Therapeutics Inc., Moonwalk Biosciences
14rounds0led - 5OrbiMed
Star Therapeutics, Leal Therapeutics, Accro Bioscience
11rounds1led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.